Advertisement
A vs MTD
Which Stock Would AI Choose? Agilent Technologies (A) vs. Mettler-Toledo International (MTD) Stock Comparison
Key Takeaways
- Agilent Technologies (A) reported a strong Q2 2026 earnings beat with raised full-year guidance, contributing to approximately 11.9% stock gains over the past month.
- Mettler-Toledo International (MTD) delivered solid Q2 2026 results including an adjusted EPS beat and received a Buy rating upgrade from Zacks, reflecting improved earnings estimates.
- Both companies operate in the precision instruments and life sciences tools sector, with Agilent offering broader exposure across life sciences, diagnostics, and applied markets while Mettler-Toledo focuses on weighing and analytical solutions.
- Recent market activity shows Agilent with stronger year-to-date performance compared to Mettler-Toledo amid varying sector sentiment.
- Upcoming earnings for Agilent on August 26, 2026, represent a near-term catalyst, whereas Mettler-Toledo continues to benefit from institutional interest following its recent report.
- Relative positioning highlights trade-offs between Agilent’s growth momentum and Mettler-Toledo’s established margin profile and stability.
Introduction
This comparison examines Agilent Technologies (A) and Mettler-Toledo International (MTD), two established players in the scientific instruments and measurement solutions space. Both companies serve laboratory, industrial, and research customers with precision tools that support analytical workflows. Traders and investors focused on sector rotation, earnings momentum, or relative valuation within healthcare-adjacent industrials may find the analysis relevant. The review emphasizes observable performance trends, business drivers, and positioning over the recent period to support informed evaluation of these stocks in the current market environment.
Agilent Technologies (A) Overview and Recent Performance
Agilent Technologies provides instruments, software, and services for life sciences, diagnostics, and applied chemical markets. Recent market activity reflects positive sentiment following the company’s Q2 2026 earnings release, which featured revenue of $1.835 billion, up 10% year over year, and non-GAAP EPS of $1.49 that exceeded estimates. Management raised full-year revenue guidance to a range of $7.39 billion to $7.49 billion. The stock advanced notably over recent weeks, with gains supported by the earnings beat and outlook revision. Broader market conditions and analyst attention ahead of the August 26, 2026, earnings report have contributed to sustained interest in the name.
Mettler-Toledo International (MTD) Overview and Recent Performance
Mettler-Toledo International specializes in precision instruments for weighing, analytical, and inspection applications across laboratory and industrial settings. The company reported Q2 2026 results that included approximately $1 billion in sales and adjusted EPS of $11.46, surpassing consensus estimates. A subsequent Buy rating upgrade from Zacks highlighted improving earnings visibility. Over recent weeks, the stock has consolidated following post-earnings movement, with performance influenced by ongoing demand for its core products and capital allocation discipline. Institutional flows and margin trends have shaped sentiment in the period.
Trending AI Robots
Tickeron maintains a curated Trending AI Robots section that highlights select AI trading bots from a broader library of hundreds available across thousands of tickers. Only those demonstrating suitability for prevailing market conditions earn placement in this focused listing. The bots encompass varied trading styles, strategies, timeframes, performance metrics, and ticker universes, enabling users to review statistical profiles before engagement. This resource provides factual data on bot characteristics to assist market participants evaluating automated approaches. Review the Trending AI Robots page for current details.
Head-to-Head Comparison
Agilent Technologies and Mettler-Toledo International share exposure to laboratory and industrial end markets yet differ in scope and drivers. Agilent’s broader portfolio across life sciences and diagnostics supports diversified revenue streams, while Mettler-Toledo’s emphasis on weighing and analytical solutions delivers focused margin characteristics. Recent momentum favors Agilent following its earnings beat and guidance raise, contrasting with Mettler-Toledo’s steadier post-report consolidation. Risk factors include Agilent’s upcoming quarterly catalyst versus Mettler-Toledo’s sensitivity to industrial capital spending cycles. Market sentiment reflects both names’ positioning within precision tools, with relative performance influenced by earnings visibility and sector rotation patterns rather than identical catalysts.
Tickeron AI Verdict
Based on observable factors including recent earnings momentum, guidance revisions, and trend consistency, Tickeron’s AI systems would currently assign a modestly higher probabilistic weighting to Agilent Technologies (A) over Mettler-Toledo International (MTD). The assessment incorporates Agilent’s stronger short-term price action and near-term catalyst alongside Mettler-Toledo’s established stability, without implying certainty or forward guarantees.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is A is a StrongBuy and MTD is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
A’s FA Score shows that 2 FA rating(s) are green whileMTD’s FA Score has 1 green FA rating(s).
- A’s FA Score: 2 green, 3 red.
- MTD’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
A’s TA Score shows that 4 TA indicator(s) are bullish while MTD’s TA Score has 5 bullish TA indicator(s).
- A’s TA Score: 4 bullish, 4 bearish.
- MTD’s TA Score: 5 bullish, 4 bearish.
Price Growth
A (@Medical Specialties) experienced а -3.13% price change this week, while MTD (@Medical Specialties) price change was -1.87% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +1.08%. For the same industry, the average monthly price growth was +11.48%, and the average quarterly price growth was +31.94%.
Reported Earning Dates
A is expected to report earnings on Nov 30, 2026.
MTD is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Medical Specialties (+1.08% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| A | MTD | A / MTD | |
| Capitalization | 42.3B | 27.6B | 153% |
| EBITDA | 1.96B | 1.3B | 151% |
| Gain YTD | 10.848 | -1.308 | -830% |
| P/E Ratio | 29.57 | 31.02 | 95% |
| Revenue | 7.23B | 4.13B | 175% |
| Total Cash | 1.81B | 51.4M | 3,516% |
| Total Debt | 3.36B | 2.11B | 159% |
A | MTD | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 24 | 68 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 10 Undervalued | 99 Overvalued | |
PROFIT vs RISK RATING 1..100 | 98 | 100 | |
SMR RATING 1..100 | 44 | 2 | |
PRICE GROWTH RATING 1..100 | 17 | 46 | |
P/E GROWTH RATING 1..100 | 42 | 48 | |
SEASONALITY SCORE 1..100 | 13 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
A's Valuation (10) in the Biotechnology industry is significantly better than the same rating for MTD (99) in the Medical Specialties industry. This means that A’s stock grew significantly faster than MTD’s over the last 12 months.
A's Profit vs Risk Rating (98) in the Biotechnology industry is in the same range as MTD (100) in the Medical Specialties industry. This means that A’s stock grew similarly to MTD’s over the last 12 months.
MTD's SMR Rating (2) in the Medical Specialties industry is somewhat better than the same rating for A (44) in the Biotechnology industry. This means that MTD’s stock grew somewhat faster than A’s over the last 12 months.
A's Price Growth Rating (17) in the Biotechnology industry is in the same range as MTD (46) in the Medical Specialties industry. This means that A’s stock grew similarly to MTD’s over the last 12 months.
A's P/E Growth Rating (42) in the Biotechnology industry is in the same range as MTD (48) in the Medical Specialties industry. This means that A’s stock grew similarly to MTD’s over the last 12 months.
| A | MTD | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 62% | 2 days ago 65% |
| Stochastic ODDS (%) | 2 days ago 58% | 2 days ago 58% |
| Momentum ODDS (%) | N/A | 2 days ago 66% |
| MACD ODDS (%) | 2 days ago 67% | 2 days ago 74% |
| TrendWeek ODDS (%) | 2 days ago 63% | 2 days ago 64% |
| TrendMonth ODDS (%) | 2 days ago 60% | 2 days ago 66% |
| Advances ODDS (%) | 7 days ago 60% | 9 days ago 61% |
| Declines ODDS (%) | 2 days ago 63% | 16 days ago 66% |
| BollingerBands ODDS (%) | 2 days ago 68% | 2 days ago 69% |
| Aroon ODDS (%) | 2 days ago 64% | 2 days ago 61% |
Advertisement